HotSpot Therapeutics to Present Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal Cancers Congress 2025
BOSTON, June 26, 2025 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting Smart Allostery platform-identified regulatory sites on proteins referred to as "natural hotspots," today announced it will present preclinical data from the Company's CARD11-BCL10-MALT1 (CBM) program in two poster presentations at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2025, taking place July 2-5, 2025, in Barcelona, Spain.
Presentation details are as follows:
Title: Synthetic lethality of CBM signalosome inhibition for KRAS-Mutant Colorectal Cancers
Poster Number: 124P
Session: Poster Display Session 2
Session Date and Time: Fri., Jul. 4, 5:30-6:30 CEST
Location: Foyer, International Barcelona Convention Center, Barcelona, Spain
Title: Novel CBM signalosome inhibitor revealed the essentiality of CBM signalosome for KRAS mutant colorectal cancer
Poster Number: 125P
Session: Poster Display Session 2
Session Date and Time: Fri., Jul. 4, 5:30-6:30 CEST
Location: Foyer, International Barcelona Convention Center, Barcelona, Spain
About HotSpot Therapeutics, Inc.
HotSpot Therapeutics, Inc. is a clinical-stage biotechnology company that is pioneering a new class of allosteric drugs that target certain naturally occurring pockets on proteins called "natural hotspots." These pockets are decisive in controlling a protein's cellular function and have significant potential for new drug discovery by enabling the systematic design of potent and selective small molecules with novel pharmacology. The Company's proprietary Smart Allostery(TM) platform combines computational approaches and AI-driven data mining of large and diverse data sets to uncover hotspots with tailored pharmacology toolkits and bespoke chemistry to drive the rapid discovery of novel hotspot-targeted small molecules. Leveraging this approach, HotSpot is building a broad pipeline of novel allosteric therapies for the treatment of autoimmune diseases and cancer. To learn more, visit www.hotspotthera.com.
HotSpot Investor & Media Contact:
Natalie Wildenradt
nwildenradt@hotspotthera.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/hotspot-therapeutics-to-present-preclinical-data-from-small-molecule-cbm-signalosome-inhibitor-program-at-esmo-gastrointestinal-cancers-congress-2025-302491489.html
SOURCE HotSpot Therapeutics
